Credit Suisse Reiterates Outperform on Galecto, Maintains $6 Price Target
Credit Suisse analyst Tiago Fauth reiterates Galecto (NASDAQ:GLTO) with a Outperform and maintains $6 price target.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Galecto Q3 EPS $(0.54) Down From $(0.50) YoY
Galecto (NASDAQ:GLTO) reported quarterly losses of $(0.54) per share. This is a 8 percent decrease over losses of $(0.50) per share from the same period last year.
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
Gainers
Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday
Gainers
Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target.
Galecto’s Myelofibrosis Candidate Reduces Bone Marrow Fibrosis
Galecto Inc (NASDAQ:GLTO) announced results from a planned intermediate assessment of its ongoing MYLOX-1 Phase 2a trial of GB2064 for myelofibrosis.…
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
Gainers
Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
SVB Leerink Maintains Outperform on Galecto, Lowers Price Target to $13
SVB Leerink analyst Mike Kratky maintains Galecto (NASDAQ:GLTO) with a Outperform and lowers the price target from $16 to $13.
69 Biggest Movers From Friday
Gainers
Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.